158 related articles for article (PubMed ID: 32074981)
1. Tigecycline Interferes with Fibrinogen Polymerization Independent of Peripheral Interactions with the Coagulation System.
Brandtner A; Bachler M; Fries D; Hermann M; Ruehlicke J; Fux V; Griesmacher A; Niederwanger C; Hell T; Treml B
Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32074981
[TBL] [Abstract][Full Text] [Related]
2. Progression of Fibrinogen Decrease during High Dose Tigecycline Therapy in Critically Ill Patients: A Retrospective Analysis.
Treml B; Rajsic S; Hell T; Fries D; Bachler M
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682825
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline-induced coagulopathy: a literature review.
Cui N; Cai H; Li Z; Lu Y; Wang G; Lu A
Int J Clin Pharm; 2019 Dec; 41(6):1408-1413. PubMed ID: 31713108
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Analysis of the Effect of Tigecycline on Coagulation Function.
Leng B; Xue YC; Zhang W; Gao TT; Yan GQ; Tang H
Chem Pharm Bull (Tokyo); 2019; 67(3):258-264. PubMed ID: 30828002
[TBL] [Abstract][Full Text] [Related]
5. Tigecycline treatment causes a decrease in fibrinogen levels.
Zhang Q; Zhou S; Zhou J
Antimicrob Agents Chemother; 2015 Mar; 59(3):1650-5. PubMed ID: 25547356
[TBL] [Abstract][Full Text] [Related]
6. High-dose fibrinogen versus a clinically recommended dose of fresh frozen plasma for reversal of dilutional coagulopathy in an in vitro model of severe hemodilution.
Rosenthal C; Rau J; Volk T; Sander M; Ziemer S; Von Heymann C
Minerva Anestesiol; 2014 Aug; 80(8):894-903. PubMed ID: 24398441
[TBL] [Abstract][Full Text] [Related]
7. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.
Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):288-93. PubMed ID: 18469550
[TBL] [Abstract][Full Text] [Related]
8. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature.
Fan Q; Huang W; Weng Y; Xie X; Shi Z
Medicine (Baltimore); 2020 Oct; 99(43):e22638. PubMed ID: 33120753
[TBL] [Abstract][Full Text] [Related]
9. Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China.
Leng B; Shen C; Gao T; Zhao K; Zhao X; Guo Y; Wu J; Yang J; Fang W; Zhang J; Zhang Y; Sun C; Duan L; Huang J; Qi Y; Yan G
Front Pharmacol; 2022; 13():943674. PubMed ID: 36304151
[No Abstract] [Full Text] [Related]
10. Mechanism of Abnormal Coagulation Induced by Tigecycline in Cancer Patients.
Sun LH; Bai KH; Wu GY; Tian XP; Zou ZQ; Wang DW; Dai YJ; Chen SL
Front Pharmacol; 2022; 13():891952. PubMed ID: 35865948
[TBL] [Abstract][Full Text] [Related]
11. Potential of whole blood coagulation reconstitution by desmopressin and fibrinogen under conditions of hypothermia and acidosis--an in vitro study using rotation thrombelastometry.
Hanke AA; Dellweg C; Schöchl H; Weber CF; Jüttner B; Johanning K; Görlinger K; Rahe-Meyer N; Kienbaum P
Scand J Clin Lab Invest; 2011 Jul; 71(4):292-8. PubMed ID: 21663556
[TBL] [Abstract][Full Text] [Related]
12. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
Haas T; Fries D; Velik-Salchner C; Reif C; Klingler A; Innerhofer P
Anesth Analg; 2008 May; 106(5):1360-5, table of contents. PubMed ID: 18420845
[TBL] [Abstract][Full Text] [Related]
13. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma.
Mischke R; Wolling H
Haemostasis; 2000; 30(3):123-30. PubMed ID: 11014962
[TBL] [Abstract][Full Text] [Related]
14. Association between standard laboratory and functional tests of coagulation in dilutional coagulopathy: an in vitro study.
Krzych LJ; Czempik PF
J Physiol Pharmacol; 2017 Aug; 68(4):637-645. PubMed ID: 29151081
[TBL] [Abstract][Full Text] [Related]
15. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.
Drews RE
Clin Chest Med; 2003 Dec; 24(4):607-22. PubMed ID: 14710693
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Tigecycline-Associated Hypofibrinogenemia.
Liu J; Yan Y; Zhang F
Ther Clin Risk Manag; 2021; 17():325-332. PubMed ID: 33888987
[TBL] [Abstract][Full Text] [Related]
17. Relationship of thromboelastography and conventional clotting test values with severe bleeding in critically ill patients with coagulopathy: A prospective study.
Casado-Méndez M; Fernandez-Pacheco J; Arellano-Orden V; Rodríguez-Martorell FJ; Díaz-Martín A; Pastor de Las Heras Á; Dusseck-Brutus R; Pérez-Torres I; Leal-Noval SR
Int J Lab Hematol; 2019 Oct; 41(5):671-678. PubMed ID: 31403249
[TBL] [Abstract][Full Text] [Related]
18. Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: relation to bleeding.
Schols SE; van der Meijden PE; van Oerle R; Curvers J; Heemskerk JW; van Pampus EC
Thromb Haemost; 2008 Jan; 99(1):64-70. PubMed ID: 18217136
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen Mahdia: A congenitally abnormal fibrinogen characterized by defective fibrin polymerization.
Amri Y; Jouini H; Becheur M; Dabboubi R; Mahjoub B; Messaoud T; Sfar MT; Casini A; de Moerloose P; Toumi NEH
Haemophilia; 2017 Jul; 23(4):e340-e347. PubMed ID: 28594476
[TBL] [Abstract][Full Text] [Related]
20. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
